Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q2 2019 10-Q quarterly report on Aug 7, 2019 for the quarter ended Jun 30, 2019.
Teva Pharmaceutical Industries Ltd Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,337M, down 8% YoY, driven by COPAXONE competition and lower TREANDA/BENDEKA sales
- Operating margin negative 14.8% vs negative 0.3% YoY, with operating loss $644M vs $14M
- Best product growth: AUSTEDO revenue $96M, up 117%; worst: ProAir revenue $65M, down 44%
- Cash flow used in operations $227M vs $162M generated YoY; cash and investments $2,232M vs $2,040M
- Headwinds: FDA warning letter, valsartan recall impact $55M, opioid provisions, expected 2019 non-GAAP tax rate 16%
Risk Factors
- Risk Factors section contains no substantive risk-factor text, only an Item 1A heading
- $1,700 million senior notes due July 2019, with approximately $144 million repurchased and canceled during six months
- Opioid litigation identified as a legal exposure through a dedicated filing taxonomy member
- Cross-currency swaps with $500 million notional amounts maturing in 2020, limiting foreign-exchange risk coverage
- Multiple senior-note maturities from 2019 through 2046, indicating substantial refinancing exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.